Plain-English translation of NCT06357182 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new combination of three medications: , , and —to treat newly diagnosed acute myeloid leukemia (a serious blood cancer) in patients who are not eligible for or do not want standard intensive chemotherapy. Researchers want to find the safest and most effective dose of this medication combination and see how well it works at helping patients go into remission. The study will enroll about 30 patients and carefully monitor their response to treatment.
Acute myeloid leukemia is a serious blood cancer, but many patients cannot receive the standard chemotherapy treatments because of age, other health conditions, or other reasons. This trial exists to offer a new treatment option for these patients and to figure out the best way to combine these three medications to fight the cancer safely.
You likely qualify if…
You likely don't qualify if…
You will take three oral medications on a repeating 28-day cycle. The first medication () is taken by mouth on specific days (days 1–5, 8–12, and 15–19 of each cycle), while the other two medications are taken on different schedules throughout the month. You will have regular blood tests and bone marrow biopsies to check how you are responding to treatment, as well as heart imaging scans at the beginning and as needed during the trial. If your cancer responds well after the first cycle, you will continue with the treatment as long as it is working and you are tolerating it well.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
United States